{"entity":{"id":"neon-therapeutics","kind":"company","name":"Neon Therapeutics","aka":["Neon Therapeutics, Inc.","BioNTech US Inc."],"tldr":"Neon Therapeutics worked on cancer treatments that point the immune system at neoantigens, the changed proteins found only on a person's cancer cells. BioNTech bought it in 2020 and it became BioNTech's US base.","summary":"Neon Therapeutics was an immuno-oncology company developing neoantigen-targeted therapies that direct the immune system towards neoantigens (Third Rock Ventures). BioNTech closed its all-stock acquisition of Neon (Nasdaq: NTGN) on 6 May 2020, after announcing the agreement on 16 January 2020. The Cambridge, Massachusetts subsidiary was to operate as BioNTech US Inc. and serve as BioNTech's US headquarters.","asOf":"2026-11-04","links":[{"label":"BioNTech completes acquisition (Neon 8-K exhibit, 6 May 2020)","url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418720000050/ntgn-20200506xex991.htm"},{"label":"Third Rock Ventures portfolio entry","url":"https://www.thirdrockventures.com/portfolio/neon"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Named product candidates are not stated in the sources read; none recorded.","Founding year not stated (2015 is Third Rock's year of investment).","No ClinicalTrials.gov studies matched the sponsor name 'Neon Therapeutics'."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","stage":"acquired","investors":["third-rock-ventures"],"funding":[],"acquiredBy":"biontech"},"route":"/companies/neon-therapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"},{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","route":"/companies/third-rock-ventures/"}]}}